Entropy Neurodynamics (ASX:ENP) said the Australian Patent Office has granted it an Australian patent titled Psilocin Crystalline Forms, providing composition-of-matter protection over multiple proprietary crystalline forms of psilocin, including novel salt and cocrystal forms designed to improve its stability, solubility, and pharmaceutical properties, according to a Friday Australian bourse filing.
The company said the patent claims also cover manufacturing methods, pharmaceutical formulations, and therapeutic applications across a range of neuropsychiatric disorders, with the patent remaining in force until September 2043.